Pershing Square, the Ackman Oxman Institute, and an undisclosed leading life sciences investment fund co-led the round. Additional participants include the Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, JSL Health Capital, and others.
“We have learned that the brain can recover from even catastrophic injury, and that there is far more that can be done for people living with neurological injuries,” said Bill Ackman, CEO of Pershing Square and co-founder of the Ackman Oxman Institute, in a news release posted yesterday. “Neurotechnology will be central to the next generation of cures, treatments, and rehabilitation. It will also produce some of the most important and valuable companies of our time that will improve the lives of millions of people. Precision has the team, technology, and ambition to be a leader in BCI, and we are therefore delighted to invest in the company.”
The Series D brings the total raised for New York–based Precision Neuroscience to $430 million. Since its founding in 2021, the company has built a large and clinical footprint in BCI, with more than 100 patient procedures across 18 medical institutions. Other achievements have included FDA clearance in April 2025 for its Layer 7 cortical interface, a commercial partnership with Medtronic, and a wholly owned MEMS manufacturing facility in Texas.
Layer 7 sits on top of the brain and causes no damage to brain tissue. Its 1,024 electrodes are embedded in a flexible film that conforms to the brain surface. (In contrast, Elon Musk’s Neuralink has BCI technology with flexible threads with microscopic electrodes implanted into the brain. Synchron, meanwhile, embeds electrodes into a catheter-delivered BCI stent.)
The money from the Series D will fund Precision Neuroscience’s clinical program, advance Layer 7 through the next stages of FDA review, and build the infrastructure needed for commercialization.
“The next phase of BCI will be defined by more than technology alone,” said Michael Mager, Precision’s co-founder and CEO. “We have built the clinical network, regulatory position, and manufacturing base that leadership in this field requires. We are also putting safety at the center of our product design, forming deep partnerships with the world’s leading neurosurgeons and academic medical centers, and building a company and a culture that we hope will endure. We’re proud to have investors who share that long-term vision.”
